SCHEMBL6805622

SCHEMBL6805622

O=C(Nc1cncn(C(C(=O)O)c2ccc(Br)cc2)c1=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
HDAC2 Q92769 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 2/20 0.40
GPR35 Q9HC97 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HIF1A Q16665 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CYP24A1 Q07973 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MDM4 O15151 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805321 0.92 IDO1 (0.47) IDO1TDO2SMN1; SMN2KDM4DKDM4C
SCHEMBL6802997 0.89 RAB9A (0.47) IDO1TDO2SMN1; SMN2KDM4DKDM4C
SCHEMBL6805808 0.89 SMN1; SMN2 (0.47) IDO1TDO2SMN1; SMN2KDM4DKDM4C
SCHEMBL6803439 0.89 ALDH1A1 (0.47) IDO1TDO2SMN1; SMN2KDM4DKDM4C
SCHEMBL6805953 0.88 IDO1 (0.41) IDO1TDO2SMN1; SMN2KDM4DKDM4C
SCHEMBL6799314 0.86 RAB9A (0.49) SMN1; SMN2HDAC2MAPTMEN1KMT2A
SCHEMBL6803978 0.85 KMT2A (0.47) SMN1; SMN2MAPTMEN1KMT2ACYP11B1
SCHEMBL6803679 0.83 RAB9A (0.50) SMN1; SMN2HDAC2MEN1KMT2ARXFP1
SCHEMBL6810352 0.81 NPC1 (0.47) SMN1; SMN2MAPTMEN1KMT2ATP53
SCHEMBL6800417 0.79 IDO1 (0.48) IDO1TDO2SMN1; SMN2KDM4DKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS IDO1 932/4885TDO2 2114/4885SMN1; SMN2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.